This contagious respiratory disease results in upwards of 80,000 hospitalizations in the United States annually among children aged younger than 5 years, and infants are especially vulnerable.
The chief objectives are to reduce the patient’s symptom duration and severity, prevent both acute and delayed complications, and forestall an overspill of the infection to others.
HEPLISAV-B™